Axalbion Announces Positive Findings from Phase 2 Clinical Study in Chronic Cough with AX-8, a Novel TRPM8 Agonist

AX-8 reduces cough frequency and improves patient-reported outcomes in patients with chronic cough Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat

Related Keywords

Manchester ,United Kingdom ,Leicester ,Switzerland ,David Julius ,Ardem Patapoutian ,Kostenloser Wertpapierhandel ,Susan Kinkead ,Michael Kitt ,Jacky Smith ,Axalbion Therapeutics ,Kinkead Communications ,University Of Manchester ,Leicester Cough Questionnaire ,Chronic Cough ,Mountain View ,Executive Officer ,Therapeutics Limited ,Axalbion ,Nnounces ,Positive ,Findings ,Rom ,Hase ,Linical ,Study ,Hronic ,Dough ,Novel ,Rpm8 ,Agonist ,